Catalyst Pharmaceuticals Reports Strong Second Quarter 2024 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/8/2026
- S&P 500 falls as AI worries hit software makers
- Brent crude hits six-week high near $97 as Houthi strike targets Saudi Aramco
- Qualcomm stock surges 9.5% on Amazon AI deal & 25M share warrant
- Energy stocks rise premarket as oil prices climb on Middle East supply fears
- Novartis shares plunge 10% as failed drug trial clouds growth outlook
- Harry and Meghan surprised by King Charles' letter on their status
- Citi initiates UiPath coverage with Buy rating and $23 target
- S&P 500 falls as AI worries hit software makers
- WestPark Capital Starts Akebia Therapeutics (AKBA) at Buy
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Catalyst Pharmaceutical Partners (CPRX) PT Raised to $31 at Citi
August 9, 2024 4:56 AM EDTCiti analyst Samantha Semenkow raised the price target on Catalyst Pharmaceutical Partners (NASDAQ: CPRX) to $31.00 (from $27.00) while maintaining a Buy rating.
The analyst comments "There was a lot to like in Catalysts 2Q print, as we outlined in our initial take, with... More
Catalyst Pharmaceuticals (CPRX) Tops Q2 EPS by 33c, Beats on Revenue; Offers FY24 Revenue Guidance
August 7, 2024 4:24 PM EDTCatalyst Pharmaceuticals (NASDAQ: CPRX) reported Q2 EPS of $0.56, $0.33 better than the analyst estimate of $0.23. Revenue for the quarter came in at $122.7 million versus the consensus estimate of $111.77 million.
GUIDANCE:
Catalyst Pharmaceuticals sees FY2024 revenue of $455-475 million, versus the consensus of... More
